JW Shinyak Corporation
JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea. The company offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesi… Read more
JW Shinyak Corporation - Asset Resilience Ratio
JW Shinyak Corporation (067290) has an Asset Resilience Ratio of 0.06% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how JW Shinyak Corporation's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down JW Shinyak Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩38.72 Million | 0.06% |
| Total Liquid Assets | ₩38.72 Million | 0.06% |
Asset Resilience Insights
- Limited Liquidity: JW Shinyak Corporation maintains only 0.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
JW Shinyak Corporation Industry Peers by Asset Resilience Ratio
Compare JW Shinyak Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AGP Ltd
KAR:AGP |
Pharmaceuticals | 0.71% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620 |
Pharmaceuticals | 4.28% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Sam-A Pharm. Co. Ltd
KQ:009300 |
Pharmaceuticals | 34.37% |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040 |
Pharmaceuticals | 5.22% |
|
WooGene B&G Co. Ltd
KQ:018620 |
Pharmaceuticals | 3.35% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 61.00% |
Annual Asset Resilience Ratio for JW Shinyak Corporation (2007–2024)
The table below shows the annual Asset Resilience Ratio data for JW Shinyak Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.42% | ₩7.83 Billion | ₩63.04 Billion | -21.71pp |
| 2023-12-31 | 34.13% | ₩22.39 Billion | ₩65.62 Billion | +25.09pp |
| 2022-12-31 | 9.03% | ₩8.50 Billion | ₩94.09 Billion | +3.04pp |
| 2021-12-31 | 5.99% | ₩5.51 Billion | ₩92.00 Billion | +2.72pp |
| 2020-12-31 | 3.27% | ₩3.15 Billion | ₩96.33 Billion | -26.07pp |
| 2019-12-31 | 29.34% | ₩40.16 Billion | ₩136.85 Billion | +24.16pp |
| 2018-12-31 | 5.18% | ₩5.66 Billion | ₩109.21 Billion | -2.59pp |
| 2017-12-31 | 7.77% | ₩9.58 Billion | ₩123.36 Billion | -4.46pp |
| 2016-12-31 | 12.23% | ₩17.56 Billion | ₩143.61 Billion | +12.20pp |
| 2015-12-31 | 0.03% | ₩42.36 Million | ₩127.68 Billion | -6.95pp |
| 2014-12-31 | 6.99% | ₩8.87 Billion | ₩126.99 Billion | -1.74pp |
| 2013-12-31 | 8.73% | ₩11.03 Billion | ₩126.32 Billion | +8.62pp |
| 2012-12-31 | 0.11% | ₩127.89 Million | ₩115.25 Billion | +0.00pp |
| 2011-12-31 | 0.11% | ₩113.55 Million | ₩102.79 Billion | -1.49pp |
| 2008-12-31 | 1.60% | ₩723.14 Million | ₩45.27 Billion | -2.91pp |
| 2007-12-31 | 4.51% | ₩2.20 Billion | ₩48.85 Billion | -- |